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A group of three rhesus macaques were inoculated with SIV isolated from a human (SIVhu) accidentally exposed and infected
with SIVsm. Extensive sequence analyses of SIVhu obtained from the human and macaques following infection indicated the
presence of truncated nef. Not only did nef fail to repair itself in vivo postinfection (p.i.), but instead, further mutations added
additional stop codons with increasing time p.i. Infection of these animals was associated with minimal acute viral replication,
followed by undetectable plasma viral loads and only intermittent PCR detection up to 5 years p.i. The three SIVhu infected and
three control monkeys were then challenged with the heterologous highly pathogenic SHIV89.6p. All three controls became
infected and showed rapid declines in peripheral CD41 lymphocytes, disease, and death at 10 and 32 weeks p.i., respectively. In
contrast, all three animals previously infected with SIVhu are healthy and exhibit stable CD41 lymphocyte levels and undetectable
plasma viral loads at .20 months post-SHIV89.6p challenge. Only transient, low levels of SHIV replication were noted in these
animals. Whereas responses to SIVgag/pol were noted, no evidence for SIV/SHIV envelope cross-reactivity was detected by
antibody or CTL analyses, suggesting that the protective immune mechanisms to the heterologous challenge isolate were most
likely not directed to envelope but rather to other viral determinants. © 2000 Academic Press
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Despite intense research efforts, the immune mecha-
nisms that confer protection from lentiviral infection or len-
tiviral-induced disease remain ill defined. The current state
of findings suggests that type 1 cell-mediated responses
are the most effective antiviral defense, exemplified and
highlighted by the observations that progression of disease
often coincides with the loss of such responses (Clerici and
Shearer, 1994). However, there is as yet no consensus on
the precise nature of a single or a spectrum of cellular
responses that provide such protection against lentivirus
infections. Current vaccine efforts are targeted at promoting
type 1 cellular responses using a variety of strategies,
which include class I-specific antigen presentation using
viral or DNA vectors, or adjuvants considered specific for
the development of Th1 type of cellular responses (Moore
et al., 1999; Wilson et al., 1999; Kim et al., 1999; Benson et
al., 1998). Despite considerable efforts in this field, the best
protection against lentiviral infection and lentivirus-induced
disease to date has been achieved with the use of live
attenuated lentiviruses (Daniel et al., 1992; Wyand et al.,
1999; Almond et al., 1995; Norley et al., 1996; Shibata et al.,
1 To whom correspondence and reprint requests should be ad-
ressed at Winship Cancer Institute, Clifton Road, Atlanta, GA 30322.
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1941997; Igarashi et al., 1997). However, the use of attenuated
lentiviruses as prophylactic vaccines was recently high-
lighted as an unacceptable option because of significant
safety concerns, including residual pathogenicity for immu-
nocompromised individuals, a distinct potential of reversion
to a fully pathogenic phenotype in vivo (Stahl-Hennig et al.,
1996; Whatmore et al., 1995; Baba et al., 1995, 1999; Rup-
recht et al., 1996), and the risk of transmission with increase
in virulence upon passage (Edmonson et al., 1998).
Live attenuated lentiviral models are nonetheless in-
valuable for the delineation of viral determinants and the
quality and magnitude of immune responses that confer
protective immunity. In this regard, our laboratory has
been both monitoring the accidental infection of a human
with SIVsm and assessing the pathogenicity of the
SIVhu2 isolated from this individual in three rhesus ma-
caques (Khabbaz et al., 1994; and manuscript in prepa-
ration). Extensive analyses of the SIVhu isolate showed
2 Abbreviations used: AID50, animal infectious dose; cpm, counts per
inute; CTL, cytotoxic lymphocytes; HIV, human immunodeficiency
irus; PBMC, peripheral blood mononuclear cells; PCR, polymerase
hain reaction; pCTL, CTL precursors; PHA, phytohemagglutinin; p.i.,
ostinfection; RT-PCR, reverse transcription–polymerase chain reac-
ion; SIV, simian immunodeficiency virus; SIVhu, SIV isolated from a
uman accidental infection; SHIV89.6p, simian/human immunodefi-
iency virus; TCID50, tissue infectious dose; VV, vaccinia virus.
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195PROTECTION INDUCED BY SIVhuthe presence of a four-base-pair deletion in nef, leading
to a frameshift and early truncation of the open reading
frame. Studies of the nef gene in the three infected
macaques showed that not only did nef fail to repair itself
in all three macaques in vivo but, in addition, further
mutations occurred upstream of the deletion, leading to
further truncation of this viral gene segment. Studies of
the immune response from these monkeys showed that
all three animals developed modest antiviral antibody
titers, retained stable CD41 T-cell counts and remained
ealthy for up to 5 years postinfection (p.i.). Detection of
irus infection was confirmed only by intermittent direct
BMC DNA PCR-positive results. To determine whether
hese macaques had developed protective immunity and
o address the potency and breadth of this potential
rotective immunity, these macaques were challenged
ith the highly pathogenic heterologous SHIV89.6p
Reimann et al., 1996, 1999) rather than a homologous
IV isolate.
RESULTS
nfection of macaques with SIVhu
The 1989 accidental infection of a laboratory worker
ith SIVsm was reported to be apathogenic with sus-
ained antiviral antibody titers and normal CD41 T-cell
evels (Khabbaz et al., 1994; and manuscript in prepara-
ion). To determine the pathogenicity of SIVhu in its
riginal host, 100 TCID50 of this uncloned isolate were
inoculated in three juvenile (,2 years of age) rhesus
macaques intravenously. For purposes of control, three
additional macaques received 100 TCID50 of the un-
cloned pathogenic parent isolate SIVsmB670. Although
all three control animals developed high viral loads,
SIV-related disease, and died within 6–15 months p.i., the
SIVhu-infected macaques did not show any clinical se-
quelae for up to 5 years p.i. and exhibited peripheral
CD41 T-cell levels indistinguishable from those of age-
matched uninfected control macaques. Plasma viral
loads were determined at 3 weeks postinfection with
SIVhu and were 1216, 759, and 723 copies/ml of plasma,
respectively, which was .3 logs below the viral loads
TABLE 1
Plasma Viral Loads Post SIVhu Versus SIVsmB670 Infection
(Viral Copies/ml Plasma)
Viral isolate 3 weeks p.i. 6 months p.i.
SIVsmB670 RFp-3 577,153 708,826
RPq-3 102,119 113,839
Rab-4 333,168 235,372
SIVhu RZv-3 1,216 ,100
RPo3 723 ,100
RCq-3 759 ,100noted in the three SIVsmB670-infected monkeys sam-
pled at the same time point (Table 1). At 6 months p.i.,however, plasma viral loads were undetectable in all
three SIVhu-infected monkeys (,100 copies/ml), while
significant replication was maintained in the control
SIVsmB670-infected macaques (Table 1).
Detection of proviral DNA sequences in sequential
PBMC samples was consistently positive in 2/3 SIVhu-
infected monkeys for LTR and/or nef during the first 8
months p.i., but was intermittent thereafter (Table 2).
SIV proviral DNA was detected only once during the
acute infection period in PBMC samples from the third
monkey (Table 2). These data were concordant with
the serology data, in which the highest anti-SIV titers
(1:6400–12,800) were found in monkey RZv-3 from
which PBMC DNA sequences were most consistently
detected (Fig. 1). Monkey RPo-3, on the other hand,
showed markedly lower titers (1:400), correlating with
the results of PBMC DNA, which were consistently
negative for the detection of proviral sequences. It is
to be noted that these titers were significantly lower
than the EIA titers (1:12,800–1:110,000) observed in the
three SIVsmB670-infected control monkeys (manu-
script in preparation). Of interest was also an apparent
increase in antibody titers in 2/3 SIVhu-infected mon-
keys between Years 2 and 3 p.i., potentially the result
of an undocumented reactivation of viral replication.
However, after 5 years postinfection with SIVhu, the
only evidence for infection in all three animals was a
modest serum antibody titer and intermittent positive
PCR results in only 1/3 animals. In addition, DNA
isolated from PCR-positive monkey PBMC samples did
not provide evidence for repair of the nef gene in vivo
(Table 3), whereas the majority of nef sequences ob-
TABLE 2
PBMC DNA PCR Analysis
Time p.i.
nef /LTR
RCq3 RPo3 RZv3
3 weeks 1/1 2/1 2/1
6 weeks 2/1 2/2 1/1
12 weeks 1/1 2/2 1/1
18 weeks 1/2 2/2 1/1
26 weeks 2/1 2/2 2/1
34 weeks 1/1 2/2 1/1
42 weeks 2/1 2/2 2/2
52 weeks 2/2 2/2 1/1
15 months 2/2 2/2 2/1
18 months 2/2 2/2 2/2
21 months 2/2 2/2 1/1
24 months 2/2 2/2 2/1
30 months 2/2 2/2 1/1
33 months 2/2 2/2 2/2
52 months 2/2 2/2 1/1
Note. PCR analyses performed for nef and LTR sequences on the
same DNA samples. 1, the sensitivity of both PCR assays was five
copies or less/sample (1.5 3 105 PBMC DNA).
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196 VILLINGER ET AL.tained from the SIVsmB670-infected monkeys coded
for a full-length protein. Instead, additional stop
codons appeared with time in the SIVhu-infected ma-
caques RZv-3 and RCq-3 (from which nef sequences
ould be amplified), upstream of the original deletion,
eading to further truncation of the translated nef open
eading frame (ORF).
HIV89.6p challenge
It was reasoned that these animals had developed
otent antiviral immune control mechanisms; we there-
ore decided to test the efficacy and the breadth of these
rotective mechanisms. Thus, we chose SHIV89.6p, a
ast-replicating, pathogenic isolate based on its unre-
ated envelope and related but heterologous gag and pol
enes (91 and 90% amino acid homology, respectively) to
he SIVhu isolate as the challenge isolate. The three
T
Analysis of Nef ORFs in SIVhu- and
Monkey Date
Nef protein
Truncated Full-leng
SIVHU-RCq3 3 weeks 1/1 0/1
12 weeks 1/1 0/1
18 weeks 8/8 0/8
34 weeks 7/7 0/7
IVHU-RZv3 18 weks 3/3 0/3
34 weeks 21/21 0/21
52 weeks 7/7 0/7
21 months 13/13 0/13
IVB670-RAb4 26 weeks 1/7 6/7
SIVB670-RFp3 26 weeks 4/10 6/10
SIVB670-RPq3 26 weeks 0/7 7/7
52 weeks 3/7 4/7
FIG. 1. Reciprocal anti-HIV-2 antibody titersa As determined by in vitro transcription/translation and polyacrylamide geIVhu-infected monkeys and three SIV naive control age-
atched macaques were subjected to an intravenous
hallenge with 200 AID50 of the highly pathogenic
SHIV89.6p isolate (Reimann et al., 1999).
One hallmark of infection of macaques with this iso-
late is a rapid loss of peripheral CD41 T cells (Reimann
et al., 1999), leading to almost undetectable levels 2–3
weeks p.i. As illustrated in Fig. 2A, these observations
were confirmed in all three control animals. In contrast,
the frequencies of CD41 PBMC in all three SIVhu-prein-
ected monkeys showed only a transient decrease at 2
nd 3 weeks p.i., which returned to prechallenge levels
hereafter (Fig. 2B). In concordance with previous re-
orts, the three control macaques developed clinical
asting and had to be euthanized within 2.5 to 8 months
ostchallenge, whereas all three SIVhu-preinfected ma-
aques are currently alive 20 months postchallenge.
B670-Infected Rhesus Macaques
Nef protein sizea
34 kDa 24 kDa ,14.3 kDa Other
1
1
8
7
1 2
1 19 1 (16kDa)
7
13
6 1 (28kDa)
6 2 2 (28kDa)
7
4 1 1 1 (28kDa)
ed following SIVhu infection of macaques.ABLE 3
SIVsm
thl separation.
s of c
197PROTECTION INDUCED BY SIVhuAnalyses of serological responses
Analyses of antibody responses were performed using
a discriminatory EIA procedure based on gp41 peptides
specific for HIV-1 versus HIV-2/SIV (Fig. 3). All three
control monkeys failed to show any detectable antibody
response to either the HIV-1 or HIV-2 peptide p.i., a
reaction typically observed after infection with this highly
pathogenic isolate (Reimann et al., 1999) or in fast pro-
gressor monkeys following SIVmac251 infection (Folks et
al., 1997). The SIVhu-preinfected monkeys had antibod-
ies specific for the HIV-2/SIV-specific peptide, but not for
the HIV-1-specific peptide at the time of SHIV challenge.
FIG. 2. Kinetics of the CD41 T-cell frequencies in PBMC sample
post-SHIV89.6p (B) inoculation.FIG. 3. Differential antibody reactivities against HIV-1 and HIV-2 gp41 peptid
and after challenge with SHIV89.6p.Determination of serum neutralization antibody titers is
currently being evaluated against SIVsm and SHIV89.6p;
however, it is doubtful that significant neutralization of
SHIV89.6p will be observed in SIVhu-infected monkeys
prior to SHIV challenge. Unlike their control counterpart,
all three SIVhu-preinfected macaques developed high
titers to the HIV-1 gp41 peptide starting at 4 weeks
postchallenge. It is to be noted that in concordance with
the data presented in Fig. 1, monkey RPo-3 had a rela-
tively low reactivity against the HIV-2 env peptide, yet
there was no anamnestic response to this peptide after
SHIV challenge, confirming the distinct immunogenic
ontrol macaques and SIVhu-preinfected macaques prior to (A) andes (Select 1/Select 2) in control and SIVhu-preinfected monkeys before
nologi
trol str
198 VILLINGER ET AL.nature of the SIVhu and SHIV89.6p envelopes in vivo.
This finding is further highlighted by results from differ-
ential Western blot (WB) analyses using the entire spec-
trum of viral proteins, including env (Fig. 4). The reactivity
of the SIVhu sera to HIV-2 proteins at the time of
SHIV89.6p challenge were restricted to env and gag p26
protein. A clear anamnestic response to gag proteins
(p26 and, to a lesser extent, p55) was noted in all three
animals at 2–3 weeks post-SHIV challenge, whereas
there was no such enhancement noted for HIV-2 env
protein. In contrast, reactivities to HIV-1 proteins prior to
the SHIV challenge were restricted to the cross-reactive
gag p24 core protein. An anamnestic response to HIV-1
gag protein similar to the one noted in the HIV-2 panels
was observed as early as 2 weeks p.i. (mainly for mon-
keys RPo-3 and RCq-3). In contrast, antibody responses
to HIV-1 env proteins were detected only at 5 weeks
FIG. 4. Sequential analyses of serum samples from SIVhu-preinfecte
versus HIV-2 proteins following challenge with SHIV89.6p. “2” stands
stands for strong positive serum. Sequential serum samples are in chro
starting from the day of SHIV89.6p challenge (to the left of the “2” confollowing SHIV challenge, confirming the primary re-
sponse to HIV-1 env and the heterologous antigenicnature of the SIVhu and SHIV89.6p envelopes. WB anal-
yses of sera from all three control SHIV89.6p-infected
macaques failed to demonstrate reactivity to any of the
viral proteins at all times postinfection (data not shown),
confirming the EIA data and highlighting the profound
immunosuppression induced by the challenge virus in
these naive animals.
Determination of plasma viral loads
Plasma viral loads were determined before and after
SHIV89.6p challenge using a quantitative RT-PCR and
showed marked differences between control and SIVhu-
preinfected monkeys (Figs. 5A and 5B). All three control
monkeys had peak viremia levels between 106 and 107
copies/ml, whereas peak loads in plasma samples from
the SIVhu-preinfected monkeys remained consistently
5
ques RPo-3 (A), RCq-3 (B), and RZv-3 (C) by Western blot against HIV-1
ative control serum; “(1)” stands for weak positive control serum; “1”
cal order from right to left (see arrows on top of the blots) for each blot
ip) to 5.5 months postchallenge.d maca
for negbelow 10 copies/ml. However, because of the marked
variation in peak values for the control animals, the
w
v
u
p
e
a
c
D
s
S
p
t
mples
fore SH
199PROTECTION INDUCED BY SIVhudifference in peak viral loads did not reach statistical
significance (P 5 0.091). Unlike the control monkeys, in
hich high viral loads were maintained after the peak
iral loads, all three SIVhu-preinfected monkeys showed
ndetectable plasma viral loads (,100 copies/ml
lasma) after Day 50 of SHIV challenge. Thus, the differ-
nces in viral set points (measured between Weeks 11
FIG. 5. Viral detection in control and SIVhu-preinfected monkeys fo
RT-PCR are depicted for the control monkeys (A) and SIVhu-preinfected
(C) PCR-based differentiation of proviral DNA in sequential PBMC sa
challenge and from PBMC samples of control macaques collected bend 20 postchallenge) between SIVhu-preinfected and
ontrol monkeys were highly significant (P , 0.01).
t
oifferential detection of SIVhu and SHIV89.6p
equences
Since primers specific for the LTR region common to
IVhu and SHIV89.6p were used for the determination of
lasma viral loads, it remains to be established whether
he observed peaks of viral replication were secondary
SHIV89.6p challenge. Plasma viral loads determined by quantitative
ys (B). The limit of detection by this assay is 100 copies/ml of plasma.
from SIVhu-preinfected monkeys collected pre- and post-SHIV89.6p
IV89.6p inoculation.llowing
monkeo reactivation of SIVhu, superinfection with SHIV89.6p,
r a combined replication of both viruses. While quanti-
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200 VILLINGER ET AL.tative differential RT-PCR is still being developed, analy-
sis of PBMC DNA samples post-SHIV89.6p challenge
strongly suggests that the observed viral loads are es-
sentially the result of the replication of SHIV89.6p, since
positive detection of SIVhu nef was observed only in
BMC from two of the three SIVhu-preinfected monkeys,
hereas all three exhibited clear positive results for HIV
nv (Fig. 5C). The positive detection of SIVhu provirus in
onkey RPo-3 at Day 11 post-SHIV89.6p challenge sug-
ests a possible reactivation of this isolate, yet this
etection was negative for all subsequent time points
nd the absence of anamnestic antibody response to
IV-2 gp41 peptide (Fig. 3) argues against any substan-
ive reactivation of SIVhu in this animal.
nalyses of proliferative responses
Analyses of proliferative responses to SIV and
HIV89.6p determinants in PBMC samples collected
rior to and at 2 months after the SHIV89.6p challenge
howed surprisingly little change in the respective levels
f antigen-specific proliferation (Fig. 6). However, while
arked responses to gag/pol were induced and main-
ained by SIVhu in all three monkeys, responses to
IVenv were evident in only two out of the three animals.
he only significant increase in proliferative response
bserved after SHIV89.6p challenge was against SIVenv
n monkey RCq-3, suggesting potential low levels of
IVhu reactivation in this animal. It was interesting to
ote that none of the monkeys appeared to develop
ymphoproliferative responses against the HIV89.6 env at
his early time point, whereas modest levels of HIVenv
roliferation were observed with samples collected at 8
FIG. 6. Evaluation of antigen-specific proliferative responses in PB
SHIV89.6p challenge against autologous B-LCL infected with V V-SIVmonths post-SHIV89.6p challenge (data not shown). The
eason for this poor immunogenicity is unclear atpresent, and this response is being investigated longitu-
dinally using other techniques of antigen presentation.
Detection of pCTL
Analyses of CTL precursor frequencies in all three
control monkeys 8 weeks post-SHIV89.6p infection failed
to demonstrate significant responses to gag/pol or
HIV89.6 env determinants (Fig. 7). In contrast, low levels
of CTL precursors against gag/pol were detected in all
three SIVhu-preinfected monkeys (Fig. 7A). These levels
increased dramatically after SHIV89.6p challenge and
were maintained over several months (data not shown).
CTL precursor levels against SIV envelope on the other
hand were seen in only 1/3 monkeys prior to SHIV89.6p
challenge (Fig. 7C), and similar to the proliferative data,
were enhanced in 2/3 monkeys after the SHIV89.6p chal-
lenge, suggesting low levels of SIVhu reactivation in
these monkeys, since no detectable anamnestic humoral
response or SIV plasma loads were noted in these mon-
keys (Figs. 3 and 4 and data not shown). The SIVenv-
specific pCTL values were consistently lower than val-
ues obtained against gag/pol determinants. Also in con-
cordance with the proliferative data, no significant CTL
precursor frequencies against HIV89.6p were noted, ei-
ther before or after SHIV89.6p challenge. While this find-
ing was puzzling, the low level of CTL activity against this
envelope was confirmed at 11 months postchallenge
using a bulk CTL assay. Only PBMCs from RCq-3 were
able to lyse autologous targets infected with VV-
HIV89.6env at high effector-to-target ratios (data not
shown). These low and/or negative levels of pCTL to
HIV89.6 env were not secondary to technical differences
mples from SIVhu-infected monkeys prior to and at 2 months post
gag-pol, V V-SIVmac239 env, or V V-HIV89.6env versus V V-wild type.in sensitivity, since the control sample obtained from a
rhesus macaque infected with the apathogenic SHIV89.6
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201PROTECTION INDUCED BY SIVhushowed significantly higher CTL activity to this protein
(data not shown).
DISCUSSION
FIG. 7. Detection and quantitation of CTL precursor frequencies in
PBMC samples from all three SIVhu-preinfected macaques and control
macaques collected prior to SHIV89.6p challenge and at 2 months
postchallenge with SHIV89.6p. The frequencies of pCTL against SIV-
mac239 gag-pol (A), HIV89.6 env (B), or SIVmac239 env (C) were
corrected by deduction of the frequencies of precursors against V V-
wild type-infected targets for the same responders. Frequencies of
V V-wild type lytic cells were comprised within 2.1 to 12.2 per 106 PBMC
or all samples and antigens.This study shows that, despite vanishing low levels of
virus replication, infection of rhesus macaques with the
i
(naturally attenuated SIVhu isolate was able to provide
significant and lasting protective responses against in-
travenous challenge with a highly pathogenic and heter-
ologous SHIV isolate. It has to be noted that, unlike most
other live attenuated SIV tested so far, SIVhu was not
derived from macaque 251-79 (Holterman, 1999). Thus,
we hypothesize that comparison of this model/isolate
with data derived from SIVmac-derived models may pro-
vide invaluable data for the delineation of such protective
responses.
The importance of the nef gene for replication in vivo
and its role in the induction of protective immunity fol-
lowing infection with nef-deleted SIV was highlighted by
the seminal studies by Desrosiers and colleagues
(Kestler et al., 1991; Daniel et al., 1992). These observa-
tions led to a flurry of studies based on the principle that
such deletion mutants may be ideal candidates for vac-
cines against HIV (Wyand et al., 1999; Almond et al., 1995;
Norley et al., 1996; Shibata et al., 1997; Igarashi et al.,
1997). The nef gene showed a clear tendency toward
repair of the gap in vivo, correlating with the emergence
of a more pathogenic phenotype, if only minor deletions
had been engineered in this gene (Whatmore et al.,
1995). In addition, residual pathogenicity was noted in
SIV Dnef and SIV D3 when given in high doses to new-
orn monkeys and even in adult macaques after pro-
onged periods of time (Stahl-Hennig et al., 1996; What-
ore et al., 1995; Baba et al., 1995, 1999; Ruprecht et al.,
996). Attempts to further attenuate SIV Dnef led to de-
reased levels of protection, without fully relieving the
ssue of residual pathogenicity at this time (Johnson et
l., 1999; Ui et al., 1999).
In comparison, studies with other attenuated strains of
IV have generally received less attention. Extensive
tudies were previously performed using the
IVmac1A11 isolate by Marthas and colleagues at UC
avis (Lohman et al., 1994; Marthas et al., 1989, 1990;
uciw et al., 1992; Van Rompay et al., 1996). Although this
irus does not exhibit any deletion in structural or any of
he accessory genes, so far there has been no evidence
or residual pathogenicity even after oral infection of
ewborn macaques (Otsyula et al., 1996). The protection
fforded by this isolate, in general, appears to prevent
he induction of disease from challenge with pathogenic
omologous SIVmac239 and SIVmac251 isolates; how-
ver, it does not prevent the establishment of infection by
he challenge isolates (Marthas et al., 1990), similar to
he results presented in the studies reported herein.
onstruction and testing of various chimeric isolates
etween the pathogenic SIVmac239 and the apatho-
enic SIVmac1A11 suggests that multiple viral determi-
ants are responsible for the attenuated phenotype
Marthas et al., 1993). However, the breadth of protective
ffects induced by SIVmac1A11 against heterologoussolates (e.g., SIVsmE660) remains to be determined
Wyand et al., 1999). Other studies used nonpathogenic
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202 VILLINGER ET AL.isolates of HIV-2 (Marthas et al., 1990; Van Rompay et al.,
1996; Looney et al., 1998; Putkonen et al., 1990) or
SHIV89.6 (Miller et al., 1997) and were shown to provide
good protection against challenge with heterologous
pathogenic SIVmac239 isolate.
The study presented herein presents at least two
novel aspects to the field of “live attenuated” lentivirus-
induced protection. First, SIVhu was not constructed or
manipulated in the laboratory, but rather resulted from
the natural selection of an apathogenic isolate following
zoonotic transmission of a fully pathogenic virus
(SIVsmB670). Whether this selection process occurred in
the animal from which the zoonotic transmission oc-
curred or during passage in the human host will be
impossible to sort, given the fact that the exact source
and time of zoonotic infection are unknown. Extensive
production of SIV quasispecies was previously reported
predominantly during late stages of infection (Hirsch et
al., 1991). It is thus possible, although statistically doubt-
ful, that the human individual was exposed only to ap-
athogenic and nef-impaired SIVsmB670 genotype(s). An-
other likely scenario is that this individual was exposed
to a set of multiple isolates but only one established
infection in the human host, resulting from selection by
viral characteristics promoting in vivo replication distinct
from nef. Alternatively, the residual SIVhu nef open read-
ng frame may code for a protein that is sufficient to
romote viral replication in vivo since the open reading
rame still encompasses both the proline-rich central
egion as well as the arginine motif involved in binding to
he SH3-domains of Lck, hck, and the zeta chain of CD3
Greenway et al., 1999; Iafrate et al., 1997; Howe et al.,
998; Craig et al., 1999).
Another hypothesis would be that the truncated nef
plays only a minor role in the apathogenic properties of
SIVhu. During analyses of nef profiles in sooty manga-
beys naturally infected with SIVsm and rhesus ma-
caques infected with SIVsm derived from the Yerkes
mangabey monkeys, our laboratory identified two main
families of SIVsm isolates (Villinger et al., 1996) based on
their homology for the nef gene. Of interest were the
following: only isolates belonging to SIVsm family 1 were
found to induce disease in rhesus macaques (McClure
et al., 1989), despite the finding that most nef sequences
characterized from sooty mangabeys ex vivo were cod-
ing for a full-length protein. Furthermore, out of the large
number of rhesus macaques infected intravenously with
104 TCID50 of the uncloned stock of SIVsmm-9, at least
two long-term nonprogressor animals (.6-year symp-
tom-free survival) were identified, that had selected for
isolates in vivo that replicated poorly and exhibited a
deletion in the nef gene (Villinger et al., in preparation). A
logical explanation for these findings is that host-related
selection pressure might have selected for these iso-
lates most likely because of determinants other than nef.
t is to be noted that PCR-based analyses of theSIVsmm-9 stock failed to identify these isolates, suggest-
ing that they represent only a minor subpopulation
present in this stock (Courgnaud et al., 1992). A molec-
ular clone of SIVhu is currently being derived from the
original isolate obtained from the human patient, and
versions of this clone will be generated whereby full-
length nef will be restored to fully address the contribu-
tion of the truncated nef to the apathogenic and immu-
ogenic phenotype of SIVhu.
The second salient difference between the studies
eported herein and previous studies has to do with the
eterologous nature of the challenge and “immunizing”
iral isolates. Recent studies reported similar levels of
rotection from intravenous SHIV89.6p challenge after
mmunization with SIVmac239 Dnef (Wyand et al., 1999;
ewis et al., 1999). Yet, while these isolates have unre-
lated envelopes, SIVmac239 gag- and pol-encoded pro-
teins were almost identical between the challenge and
the “immunizing” isolates. In contrast, despite the evi-
dence of immune cross-reactivity to gag highlighted in
this study, SIVsm isolates and SIVhu in particular also
show divergence in gag and pol genes (only 88–90%
homology, mostly nonsynonymous) vpr, vif, rev, and tat
(72–90% homology) when compared to SIVmac239,
which constitutes the backbone of the SHIV89.6p isolate
(Reimann et al., 1996). Therefore, there is a lower level of
homology between “immunizing” and challenge lentiviral
isolates in the present study when compared to Wyand’s
SHIV89.6p-challenged monkeys (Wyand et al., 1999).
This divergence may explain the lower levels of protec-
tion induced by SIVmac239 Dnef against SIVsmE660
than against SHIV89.6p in this study. Further dissection
of mechanisms underlying these different outcomes
should clarify whether they are secondary either to an-
tigenic viral determinants or to subtle differences in
pathogenicity of both challenge isolates. It is to be noted
that the report by Lewis et al. (1999) also suggested a
more potent protection induced by SIVsm Dnef than
SIVmac239 Dnef (Wyand et al., 1999). Nevertheless, the
studies by both Putkonen (Marthas et al., 1990) and
Miller (Miller et al., 1997) and the present study suggest
that immune responses to env most likely play a minor
role in antiviral control mechanisms in vivo, which has
important implications for the design of HIV vaccine
strategies.
Based on the findings highlighted above, we submit
that protective mechanisms capable of inhibiting viral
replication and progression toward disease can be es-
tablished, provided the levels of viral replication during
the acute stage are inhibited either by viral attenuation or
with the use of select chemotherapy (Van Rompay et al.,
1995; Mori et al., 2000). However, the maintenance of
such protective mechanisms may require chronic anti-
genic stimulation afforded by infection with the attenu-
ated viruses. An elegant and appealing alternative would
be to have relevant HIV proteins expressed by another
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long infection, e.g., varicella zoster virus. Whether the
type, frequency, and site of antigen stimulation by such
constructs will achieve protection levels equivalent to
levels seen after infection with attenuated lentiviruses
remains to be shown. However, more important at
present is the delineation of viral determinants that are
capable of conferring such protection in vivo. We hypoth-
size that detailed analyses and comparison of immune
esponses observed after infection with several of these
ttenuated viruses (SIVmac1A11, SIVmac239 Dnef,
SIVhu, and other SIVsm derived from healthy long-term
nonprogressor macaques) may provide a consensus as
to which viral features are required for protective immu-
nity besides the rate of acute replication in vivo. These
studies, namely the evaluation of residual pathogenicity
in immunocompromised animals and the contribution of
nef modifications to the apathogenic phenotype of the
SIVhu isolate, are in progress and would potentially pro-
vide a better understanding of what forms a protective
response against lentivirus replication in vivo.
MATERIALS AND METHODS
Monkeys
The rhesus macaques from this study were housed at
the Yerkes Regional Primate Research Center in accor-
dance with the instructions of the Committee on the Care
and Use of Laboratory Animal Resources, National Re-
search Council, and the PHS guidelines, “Guide for the
Care and Use of Laboratory Animals.”
Virus
SIVhu was isolated from a laboratory worker infected
accidentally with biological fluids or organs of a rhesus
macaque infected with uncloned, pathogenic SIVsmB670
(Khabbaz et al., 1994). Virus isolation from this patient
was successful only once from CD8-depleted peripheral
blood mononuclear cells (PBMCs), 2.5 years after the
suspected accidental exposure (2 years postseroconver-
sion) and this isolate was termed SIVhu (Khabbaz et al.,
1994). Partial genetic analysis of SIVhu confirmed that
this isolate was derived from SIVsmmB670 (97.9% homol-
ogy versus 81.1% to SIVmac251). These studies also iden-
tified a consistent 4-base-pair (bp) deletion in nef, intro-
ducing a frameshift, aberrant translation of 23 residues,
and early termination of this accessory gene. The natu-
rally occurring 4-bp deletion is located at bp 457 of the
nef gene, corresponding to the LTR U3 region at a site
similar to the 12-bp deletion introduced in the SIVmacC8-
attenuated clone (Rud et al., 1994) but approximately 100
mino acids downstream of the SIVmac239 nef deletion
ngineered by Kestler et al. (1991). An SIVhu viral stock
as prepared in human PBMCs, of which 100 TCID50
were used to inoculate each of three animals intrave-
(
7nously. The control SIVsmB670 isolate was kindly pro-
vided by Dr. M. Murphey-Corb (Tulane Regional Primate
Research Center, Covington, LA) and was administered
at a dose of 100 TCID50 intravenously. The SHIV89.6p
challenge isolate (Reimann et al., 1996, 1999) was kindly
provided by Dr. N. Letvin (Beth Israel Hospital, Harvard
Medical School, Boston, MA) and was administered at a
dose of 200 AID50 intravenously.
Blood samples
Blood samples were obtained by venipuncture at var-
ious times post-SIVhu infection and both pre- and post-
SHIV89.6p challenge. PBMC were obtained after stan-
dard Ficoll–Hypaque gradient centrifugation.
FACS analysis of PBMC
Phenotypic analyses were performed as described
previously (Ahmed-Ansari et al., 1989) by flow cytometry
using a three-color staining procedure.
Serology
SIV-specific antibody titers were determined in mon-
key sera using whole HIV-2 EIA (HIV-1/HIV-2; Genetic
Systems, Seattle, WA). SIVenv and HIVenv differential
antibody analyses were performed with the Select-1/
Select-2 EIA (Biochem Immunosystems, Montreal, Que-
bec, Canada), specific for HIV-1 or HIV-2/SIV gp41 anti-
bodies, respectively. Reactivities were confirmed by
HIV-1- and HIV-2-specific Western blot analyses (Cam-
bridge Biotech, Worcester, MA).
Determination of plasma viral loads
Virion-associated RNA (vRNA) was quantified in
plasma samples using a reverse-transcription/polymer-
ase chain reaction (RT-PCR) prototype assay system sim-
ilar to the one detailed by Mulder et al. (1994). Briefly,
viral RNA from 300 ml of plasma spiked with 50 copies of
quantitation standard were extracted as described.
ingle-tube RT-PCR amplifications were performed using
he rTth DNA polymerase (Roche Molecular Systems,
lameda, CA), using the equivalent of 50 ml of plasma
per reaction. Primer sequences were based on LTR re-
gions cross-reactive between multiple SIV and HIV-2
strains and were biotin 59-GCTGGCAGATTGAGCCCT-
GGGAGGTTCT-39 for the forward primer and 59-GAAT-
GACCAGGCGGCGACTAGGAGAGAT-39 for the reverse
rimer. Cycling conditions were the following: initial
eating at 50°C for 2 min followed by annealing at 60°C
or 30 min to complete the RT reaction. The PCR ampli-
ication was initiated by four cycles of denaturation
95°C, 10 s), annealing (55°C, 10 s), and extension (72°C,
0 s). This was followed by 30 cycles of 90°C (10 s), 60°C
10 s), and 72°C (10 s), with a final 15-min extension at
2°C. The detection and quantitation of the denatured
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204 VILLINGER ET AL.amplicons was performed in Amplicor microwell plates
coated with a captured bovine serum albumin-conju-
gated oligoprobe (59-TGGCTGTTCCCTGCTAGACTCT-
CACCAGTACT-39). Detection of the biotinylated primer on
the captured amplicons was done using streptavidin-
horseradish peroxidase and tetramethylbenzidine (Mul-
der et al., 1994). Stocks of SIVmac251 and HIV-2NIH-Z with
ssociated particle counts and core antigen values were
ncluded in each assay, to correct for interassay variabil-
ty. The sensitivity of the assay was typically about 100
opies/ml of plasma.
etection and differentiation of SIV- versus
HIV-specific DNA sequences
DNA was isolated from PBMC and amplified with prim-
rs specific for:
1. HIV-2/SIV LTR: Primer pairs and amplification pro-
ocols were essentially utilized as described previously
or the detection of SIVhu proviral sequences presented
n Table 2 (Gao et al., 1994).
2. SIVsmm nef: First round of amplification (forward
primer 59-CGCCTCTTGACTTGGCTATTCAGC-39, reverse
primer CCTCTCCGCAGAGCGACTGAATACA-39), which
did not amplify SIVmac239 nef or SHIV89.6p nef, and a
econd round of amplification using a nested forward
rimer (59-CCAGATCCTCCAACCAGTGCTCCAG-39) and
he same reverse primer (Switzer and Heneine, 1995).
3. HIV gp41: Primers designed to cross-react with
ost HIV-1 env isolates belonging to clades A through H
ere used (Yang et al., 1999), to differentiate SHIV89.6p
rom SIVhu sequences. The primers used for the first
mplification procedure were as follows: forward primer
59-TCTTAGGAGCAGCAGGAAGCACTATGGG-39) and re-
erse primer (AACGACAAAGGTGAGTATCCCTGCCTAA-
9). A nested amplification was then performed using the
orward primer (59-ACAATTATTGTCTGGTATAGTGCAA-
AGCA-39) and reverse primer (59-TTAAACCTATCAAGC-
TCCTACTATCATTA-39). The amplification products were
hen separated through 1.5% agarose gels and stained
ith ethidium bromide. For the detection and confirma-
ion of SIV nef sequences, the amplified DNA was blotted
nto positively charged nylon membranes (Hybond N;
mersham, Arlington Heights, IL) and hybridized to a
pecific 32P-labeled oligo probe (59-AGACATGTCTCATTT-
ATAAAAGAAAAGG-39). The bound radioactivity was
hen revealed using autoradiography.
ll three amplification protocols consistently detected
ive copies or less per sample.
nalysis of SIV nef open reading frame length
The amplified nef fragments obtained as described
bove were cloned into pT7 blue-T vectors (Novagen,
adison, WI) and utilized as templates for a translation/
ranscription procedure, including 35S-labeled methio-nine and rabbit reticulocyte lysates (Promega, Madison,
WI), as described previously (Switzer and Heneine,
1995). The in vitro generated proteins were then sepa-
rated by electrophoresis onto denaturing polyacrylamide
gels along with 14C-labeled size markers and exposed to
ilm overnight.
etermination of SIV- and SHIV-specific proliferative
esponses
PBMC samples collected prior to and post-SHIV89.6p
hallenge were tested in a 5-day proliferation assay
escribed previously (Mori et al., 2000) by coculture with
utologous B-LCLs, that had been infected overnight
ith vaccinia constructs expressing SIVgag/pol (VV-gag/
ol), SIV env (VV-SIVenv), HIV89.6env (VV-HIV89.6env,
oth envelope genes had their leader sequence deleted
o prevent surface expression and syncytia formation
ith CD41 T cells; courtesy of Therion Biologicals, Cam-
bridge, MA) or wild-type vaccinia (NYCBH) overnight and
irradiated with 8000 rads. Each coculture was set in
triplicate wells of 96-well U-bottomed microplates, and
the ratio of responders to stimulators was 5 to 1 (2 3 105
responders/4 3 104 stimulators). Culture of an aliquot of
the PBMCs with 5 mg/ml of PHA-P (Difco Laboratories,
Detroit, MI) was used as a positive control. Sixteen hours
prior to collection, the cell cultures were pulsed with 1
mCi of [3H]thymidine/well overnight. The cells were then
ollected and the incorporated radioactive thymidine
as counted using a Trilux b-counter (Wallac, Turku,
Finland). A stimulation index was derived for each sam-
ple and antigen by the ratio of the mean value obtained
for each triplicate well divided by the mean triplicate
value obtained from cocultures of the same responder
sample with VV wild-type infected autologous B-LCLs
(Mori et al., 2000). This assay essentially measured
CD41 T-cell proliferation since depletion of CD41 T cells
rom PBMC samples abolished the response, and prolif-
rative responses to VV wild-type were essentially sim-
lar to proliferative responses to uninfected autologous
-LCLs (data not shown).
etermination of SIV-specific pCTL
Evaluation of circulating CTL precursors to SIVgag/pol,
IVenv, or HIV-1 89.6env were determined using a 2-week
imiting dilution assay protocol as previously described
Villinger et al., 2000). Briefly, 24 replicate wells containing
28 to 1 3 103 (8 twofold dilutions) were cultured in the
presence of 2 3 104 Herpes papio-transformed autolo-
gous B-LCLs that had been previously infected with VV-
SIVmac239gag/pol, VV-SIVmac239env, or VV-HIV89.6env
overnight and irradiated with 8000 rads. Every 2 days,
half the culture media was replaced with fresh RPMI
media containing 20 U/ml of recombinant IL-2. After
the 2-week restimulation procedure, the responder
cells were tested for lytic activity against 1 3 104 autol-
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205PROTECTION INDUCED BY SIVhuogous 51Cr-labeled B-LCL targets infected with either
accinia wild-type (NYCBH), VV-SIVmac239gag/pol, VV-
IVmac239env, or VV-HIV89.6env. After a 6-h incubation,
he radioactivity released in the culture supernatant flu-
ds was counted. The spontaneous and maximal 51Cr
release were obtained from replicate wells without ef-
fectors or by lysis of target cells with 1% of Triton X-100,
respectively. A cutoff for positive lysis for each target was
obtained from the average value obtained from the 24
replicate wells without effectors 1 3SD. The frequencies
f CTL precursors and confidence intervals were derived
sing the Jacknife program. Data presented represent
et pCTL values, where the values for each antigen were
djusted for the values obtained against targets pulsed
ith wild-type vaccinia virus by the same responder
opulation.
tatistical analyses
The data were analyzed using the single-tailed Stu-
ent’s t test.
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